Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Clinical TherapeuticsPublished 1 October 2005
Gina J. Ryan, Lynetta J. Jobe, Rhonda Martin
Citations161
SJR quartileQ1
SJR score0.98
SNIP1.02
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Use of pramlintide in addition to insulin in patients with type 1 and type 2 diabetes was associated with modest reductions in HbA(1c) and the incidence of hypoglycemia in the first 4 weeks of therapy was 2 to 4 times greater with pramsintide compared with placebo; thus, the manufacturer recommends reducing the dose of premeal insulin by 50% when starting pramlintide.
Abstract
Use of pramlintide in addition to insulin in patients with type 1 and type 2 diabetes was associated with modest reductions in HbA(1c). The primary adverse effects of pramlintide therapy were nausea and hypoglycemia.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineThe Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
24,537 Citations1993David M. Nathan
Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
The LancetIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
20,069 Citations1998
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
The LancetEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
8,213 Citations1998
Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
Diabetes CareDiagnosis and Classification of Diabetes Mellitus
1,655 Citations2004American Diabetes Association
JAMAPoor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
1,367 Citations2004Sharon Saydah
Participants with previously diagnosed diabetes in NHANES 1999-2000 were similar by age and sex, were less likely to be non-Hispanic white, were diagnosed at an earlier age, had a higher body mass index, and were more likely to use insulin in combination with oral agents.
Proceedings of the National Academy of SciencesPurification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.
1,301 Citations1987Garth J. S. Cooper, Anthony C. Willis +4 more
A peptide, of calculated molecular mass 3905 Da, that was a major protein component of amyloid-rich pancreatic extracts of three type 2 diabetic patients is described, indicating that these peptides are related in evolution.
Diabetes CareProjection of Diabetes Burden Through 2050
1,018 Citations2001James P. Boyle, Amanda Honeycutt +5 more
If recent trends in diabetes prevalence rates continue linearly over the next 50 years, future changes in the size and demographic characteristics of the U.S. population will lead to dramatic increases in the number of Americans with diagnosed diabetes.
Diabetic MedicineAmylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial
307 Citations2004Robert E. Ratner, Richard A. Dickey +6 more
This work aimed to determine the long‐term efficacy and safety of adjunctive therapy with pramlintide, a synthetic human amylin analogue, in patients with Type 1 diabetes.
Diabetes CarePramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes
301 Citations2003Priscilla Hollander, Philip T. Levy +6 more
Mealtime amylin replacement with pramlintide 120 microg BID, as an adjunct to insulin therapy, improves long-term glycemic and weight control in patients with type 2 diabetes.
NeuroscienceIn vitro autoradiographic localization of amylin binding sites in rat brain
268 Citations1994Patrick M. Sexton, George Paxinos +3 more
The distribution of amylin binding sites in rat brain is mapped and the location of binding is consistent with potential roles for these sites in appetite, fluid and electrolyte homeostasis, autonomic function and regulation of mood.
Diabetes CareA Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
260 Citations2002Fred W. Whitehouse, Davida Kruger +6 more
Mealtime pramlintide treatment as an adjunct to insulin improved long-term glycemic control without inducing weight gain or increasing the overall risk of severe hypoglycemia in patients with type 1 diabetes.
International Journal of ObesityThe anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats
218 Citations2001Ta Lutz, Andrea Mollet +3 more
Neurons in the AP/NTS region are necessary for chronically elevated peripheral amylin to reduce food intake in rats, and high doses of amyl in may be able to overrun these receptors and reduce feeding by acting at other brain sites.
Molecular PharmacologyHigh affinity amylin binding sites in rat brain.
206 Citations1993Kevin Beaumont, Mary Kenney +2 more
It is reported here that binding sites with high affinity for radioiodinated rat amylin are present in the nucleus accumbens region of rat brain, and whether salmon calcitonin shares with amyl in the ability to regulate glycogen metabolism in rat skeletal muscle is tested.
PharmacoEconomicsCost-of-Illness Studies in Diabetes Mellitus
194 Citations2004Lorraine Ettaro, Thomas J. Songer +2 more
This review examines the results of these COI studies, identifies the strengths and limitations of the various methods utilised, and suggests future research that will help determine the economic burden of diabetes more accurately.
Current Pharmaceutical DesignAmylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control
172 Citations2001C. Weyer, David J. Maggs +2 more
Pramlintide is a soluble, non-aggregating, injectable, synthetic analog of human amylin currently under development for the treatment of type 1 and insulin-using type 2 diabetes and is shown to reduce food intake and body weight, consistent with an additional satiety effect.
Diabetes CareImpact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps
155 Citations2003Claresa Levetan, Laura L. Want +9 more
The addition of pramlintide to insulin therapy reduced excessive 24-h glucose fluctuations as well as postprandial glucose, glucagon, and triglyceride excursions in patients with type 1 diabetes intensively treated with insulin pumps.
Diabetes Technology & TherapeuticsAdjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes
154 Citations2002Robert E. Ratner, Laura L. Want +6 more
The results from this study support the safety and efficacy of pramlintide administered three times a day with major meals, in conjunction with insulin therapy, for improving long-term glycemic and weight control in subjects with type 2 diabetes.
Hormone and Metabolic ResearchThe Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus
146 Citations2002Mark Fineman, C. Weyer +3 more
DiabetologiaInfusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
131 Citations1997Marie‐France Kong, P. King +6 more
Pramlintide, a human amylin analogue, reduces hyperglycaemia after meals in patients with insulin-dependent diabetes mellitus (IDDM), and may be of value in improving glycaemic control in IDDM by modifying gastric emptying.
Neurogastroenterology & MotilityEffects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
111 Citations2002Adrian Vella, J. S. Lee +6 more
Pramlintide delays gastric emptying in diabetes unassociated with clinically detected complications, possibly by a centrally mediated mechanism, and further studies are needed in diabetic patients with impaired gastric motor function.
Diabetes CarePramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes
107 Citations2003Christian Weyer, Alan Gottlieb +8 more
Pramlintide, given at or just before a meal, reduces the postprandial glucose excursion in subjects with type 1 diabetes, regardless of whether added to regular insulin or a rapid-acting insulin analog.
DiabetologiaThe effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM
105 Citations1998Marie‐France Kong, T. A. Stubbs +6 more
The purpose of this study was to examine the dose response relationship of subcutaneous injections of pramlintide on gastric emptying and to determine whether administration of the drug before one meal has an impact on the subsequent meal.
Journal of Cellular BiochemistryMolecular physiology of amylin
104 Citations1994Richard Pittner, K Albrandt +6 more
Recent evidence supports the view that amylin's effects on skeletal muscle occur, at least in large part, through activation of the cAMP pathway.
MetabolismThe amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
102 Citations1999B. Nyholm, L. Ørskov +8 more
The data indicate that pramlintide (30 microg four times daily) is capable of improving metabolic control in type 1 diabetics and may relate, in part, to suppression of glucagon concentrations.
Diabetes CarePramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin
87 Citations1998Robert G. Thompson, Leeanne L. Pearson +3 more
Reductions in serum fructosamine, plasma total and LDL cholesterol concentrations, and HbA1c support the hypothesis that pramlintide may improve metabolic control in patients with type 2 diabetes using insulin.
EndocrinologyCoexpression of Receptors for Adrenomedullin, Calcitonin Gene-Related Peptide, and Amylin in Pancreatic β-Cells1
86 Citations2000Alfredo Martı́nez, S. Kapas +3 more
Data suggest that the inhibitory effect caused by both AM and CGRP on insulin secretion is mediated by a direct interaction with the beta-cell, and implicate AM and the other components of its peptide family as important regulators of insulin release.
Diabetes/Metabolism Research and ReviewsPramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study
78 Citations2004David Maggs, Mark Fineman +7 more
To assess the postprandial glucose‐lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals.
Diabetic MedicinePramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, and C-peptide Concentrations in Patients with Type 2 Diabetes
71 Citations1997R. Thompson, Alan Gottlieb +4 more
It is suggested that administration of pramlintide may improve glycaemic control in patients with Type 2 diabetes treated with insulin or poorly controlled on diet and/or oral hypoglycaemic agents.
DiabetesEffects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial
66 Citations1997Robert G Thomas, Janet T. Peterson +2 more
Data indicate that pramlintide effectively reduces plasma glucose concentrations as reflected in both a 24-h glucose profile and a Sustacal test meal while maintaining an acceptable safety profile.
MetabolismEffect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis
63 Citations2003David Maggs, Larry Z. Shen +4 more
The combined improvement in glycemic and weight control with pramlintide treatment appears to be generalizable to a broad population of mixed ethnicity.
Diabetes Obesity and MetabolismAddition of pramlintide to insulin therapy lowers HbA <sub>1c</sub> in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets
57 Citations2003Priscilla Hollander, Robert E. Ratner +6 more
The addition of pramlintide, an analogue of the β‐cell hormone amylin, to pre‐existing insulin regimens results in reductions in HbA1c that are accompanied by weight loss.
American Journal of Health-System PharmacyProperties of pramlintide and insulin upon mixing
48 Citations2005Christian Weyer, Mark Fineman +5 more
Mixing pramlintide with short- or long-acting insulin in the same syringe before subcutaneous injection did not affect the pharmacodynamics of glucose or the pharmacokinetics of insulin or prAMLintide in a clinically significant manner.
DiabetologiaEffects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations
45 Citations1997R. Thompson, Lui R. Holder Pearson +1 more
Pramlintide improved blood glucose control over a 4-week period without increased hypoglycaemia and was well tolerated, and future studies using a longer period of pramlintide administration with assessment of HbA1c as the measurement of glycaemic control are warranted.
The Journal of PhysiologyProlactin‐releasing peptide affects gastric motor function in rat by modulating synaptic transmission in the dorsal vagal complex
28 Citations2004Gintautas Grabauskas, Shi‐Yi Zhou +4 more
Data indicate that PrRP may act within the DVC to regulate gastric motor function by modulating the efficacy of conventional excitatory synaptic inputs from the NTS onto gastric‐projecting vagal motor neurones.
EndocrinologyCoexpression of Receptors for Adrenomedullin, Calcitonin Gene-Related Peptide, and Amylin in Pancreatic -Cells
19 Citations2000Alfredo Martı́nez